Shanghai Yidi Biotechnology Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes.
Shanghai Yidi Biotechnology Co. Ltd. has disclosed neutrophil elastase (ELANE; leukocyte elastase) inhibitors reported to be useful for the treatment of pain and respiratory tract inflammation.
Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported to be useful for the treatment of spinal and bulbar muscular atrophy, prostate and breast cancer.
Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, metabolic diseases, neurological and inflammatory disorders.
Shanghai Yidi Biotechnology Co. Ltd. has identified dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or phosphodiesterase PDE4D2 inhibitors reported to be useful for the treatment of autoimmune disorders, metabolic diseases, neurological diseases and inflammatory disorders.
Shanghai Yidi Biotechnology Co. Ltd. has synthesized peptide-based nitrile compounds acting as dipeptidyl peptidase 1 (DPP-1, cathepsin C) inhibitors reported to be useful for the treatment of cancer, infections, and respiratory, metabolic, cardiovascular, cerebrovascular and autoimmune diseases.
